Dhanvantri Jeevan Rekha revenue rises 14% in FY26; profit dips
- Operating income rose 14.17% YoY to ₹258.58 crore in FY26
- Net profit fell 23% to ₹39.07 lakh due to rising operational costs
- Earnings per share dropped to ₹0.94 from ₹1.60 in the previous year
- Company remains debt-free with no long-term borrowings
- AGM scheduled for September 29, 2026, for director reappointments

*this image is generated using AI for illustrative purposes only.
Dhanvantri Jeevan Rekha Limited reported a 14.17% rise in operating income for FY26, but net profit fell 23% year-on-year as higher costs offset top-line growth. The healthcare provider will convene its 33rd Annual General Meeting on Tuesday, September 29, 2026.
The company’s standalone financial results for the fiscal year ended March 31, 2026, show continued expansion in hospital services despite margin compression. Profit after tax stood at ₹39.07 lakh compared to ₹50.61 lakh in FY25.
Financial Performance
Operating income increased to ₹258.58 crore from ₹226.50 crore in the previous year. However, other income declined from ₹41.40 lakh to ₹32.93 lakh. Total expenses rose sharply to ₹257.88 crore from ₹225.08 crore, driven by higher professional fees to doctors and medical consumables costs.
| Metric | FY26 (₹ in lakhs) | FY25 (₹ in lakhs) | Change |
|---|---|---|---|
| Operating Income | 2,585.84 | 2,265.03 | +14.17% |
| Other Income | 32.93 | 41.40 | -20.46% |
| Profit Before Tax | 40.00 | 55.59 | -28.04% |
| Profit After Tax | 39.07 | 50.61 | -22.78% |
Earnings per share (basic) dropped to ₹0.94 from ₹1.60 in FY25. The company remained debt-free during the period, with no long-term borrowings secured.
What the Numbers Show
While revenue growth indicates strong patient inflow or service utilization, the divergence between top-line growth and bottom-line contraction highlights cost pressures. Professional fees to doctors rose 10.8% to ₹80.87 crore, and employee benefit expenses increased 10.4% to ₹52.98 crore. These operational costs outpaced revenue growth, compressing the net profit ratio from 2.90% in FY25 to 1.49% in FY26.
Director Reappointments
The Board recommends the reappointment of Mr. Tulsi Prasad Sharma and Mrs. Rowena Sharma, both retiring by rotation. They are eligible under the Companies Act, 2013.
| Director | DIN | Date of Appointment | Age | Nationality |
|---|---|---|---|---|
| Mr. Tulsi Prasad Sharma | 09619078 | May 5, 2022 | 57 years | Indian |
| Mrs. Rowena Sharma | 02477356 | September 30, 2021 | 71 years | Indian |
Mr. Sharma has experience in administrative support, while Mrs. Sharma holds a B.Com degree. Neither director nor their relatives have financial interests in the resolutions beyond their shareholdings.
Meeting Logistics
The AGM will be held exclusively through video conferencing or other audio-visual means (VC/OAVM). Physical attendance is not permitted. Members can join 15 minutes before and after the scheduled start time of 3:00 pm.
Remote e-voting commences on Saturday, September 26, 2026, at 9:00 am and ends on Monday, September 28, 2026, at 5:00 pm. The cut-off date for voting eligibility is Tuesday, September 22, 2026. Central Depository Services (India) Limited (CDSL) facilitates the e-voting process.
Corporate Governance
CA Sarat Jain serves as the Scrutinizer for the remote e-voting process. The Register of Members and Share Transfer Books will remain closed from Wednesday, September 23, 2026, to Tuesday, September 29, 2026. M/s Anuj Goyal & Co. are the statutory auditors for the year.
Historical Stock Returns for Dhanvantri Jeevan Rekha
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | +0.62% | -9.24% | -21.49% | -29.88% | 0.0% |
What specific cost-control measures or pricing strategies will Dhanvantri Jeevan Rekha implement to reverse the margin compression caused by rising professional fees and medical consumables?
How does the company plan to sustain its 14% revenue growth trajectory in FY27 given the current pressure on net profit margins?
Will the reappointment of long-serving directors bring any new strategic initiatives to address the divergence between top-line growth and bottom-line performance?

































